A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Phase of Trial: Phase III
Latest Information Update: 06 Jan 2020
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Meniere's disease
- Focus Registrational; Therapeutic Use
- Sponsors Otonomy
- 05 Nov 2019 According to an Otonomy media release, the company expects to results from this trial in the third quarter of 2020.
- 28 Mar 2019 New source identified and integrated European Clinical Trials Database EudraCT2018-001464-35
- 04 Mar 2019 According to an Otonomy media release, the design and conduct of this trial is based on the AVERTS-2 trial. The company expects to complete the trial in first half of 2020.